CYCN
Cyclerion Therapeutics, Inc.Company with tickers: CYCN
CIK
1755237
CUSIP
23255M204
Shares Outstanding
4,330,314
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $81,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $2,400,000 | USD | 2023-07-28 | 10-Q | 2026-05-12 |
| Research & Development | $36,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Operating Income | $-1,457,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| Net Income | $-1,429,000 | USD | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Basic) | $-0.56 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |
| EPS (Diluted) | $-0.56 | USD/shares | 2025-03-31 | 10-Q | 2026-05-12 |